CN102105491A - 白介素-21受体结合蛋白 - Google Patents

白介素-21受体结合蛋白 Download PDF

Info

Publication number
CN102105491A
CN102105491A CN200980128968XA CN200980128968A CN102105491A CN 102105491 A CN102105491 A CN 102105491A CN 200980128968X A CN200980128968X A CN 200980128968XA CN 200980128968 A CN200980128968 A CN 200980128968A CN 102105491 A CN102105491 A CN 102105491A
Authority
CN
China
Prior art keywords
fab
conjugated protein
human
binding
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980128968XA
Other languages
English (en)
Chinese (zh)
Inventor
莱尔德·布卢姆
达文德·吉尔
尤利亚·武格梅斯特
德博拉·A·扬
戴维·洛
维亚·瓦尔格-阿彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Wyeth LLC
Original Assignee
MedImmune Ltd
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102105491(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune Ltd, Wyeth LLC filed Critical MedImmune Ltd
Publication of CN102105491A publication Critical patent/CN102105491A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200980128968XA 2008-05-23 2009-05-26 白介素-21受体结合蛋白 Pending CN102105491A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23
US61/055,500 2008-05-23
PCT/US2009/045182 WO2009143523A1 (en) 2008-05-23 2009-05-26 Interleukin-21 receptor binding proteins

Publications (1)

Publication Number Publication Date
CN102105491A true CN102105491A (zh) 2011-06-22

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980128968XA Pending CN102105491A (zh) 2008-05-23 2009-05-26 白介素-21受体结合蛋白

Country Status (20)

Country Link
US (2) US8163884B2 (cg-RX-API-DMAC7.html)
EP (1) EP2297199A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011523849A (cg-RX-API-DMAC7.html)
KR (1) KR20110040773A (cg-RX-API-DMAC7.html)
CN (1) CN102105491A (cg-RX-API-DMAC7.html)
AR (1) AR071885A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009248809A1 (cg-RX-API-DMAC7.html)
CA (1) CA2724915A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009001284A1 (cg-RX-API-DMAC7.html)
CO (1) CO6382184A2 (cg-RX-API-DMAC7.html)
IL (1) IL209328A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010012811A (cg-RX-API-DMAC7.html)
MY (1) MY149448A (cg-RX-API-DMAC7.html)
NZ (1) NZ589330A (cg-RX-API-DMAC7.html)
PE (1) PE20100141A1 (cg-RX-API-DMAC7.html)
RU (1) RU2010152690A (cg-RX-API-DMAC7.html)
SA (1) SA109300315B1 (cg-RX-API-DMAC7.html)
TW (1) TW201000129A (cg-RX-API-DMAC7.html)
WO (1) WO2009143523A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201008335B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
EP2518084B1 (en) * 2009-12-25 2016-11-30 Sekisui Medical Co., Ltd. Method for measuring human insulin and measurement reagent
EP2545080B1 (en) * 2010-03-12 2017-05-10 Alexion Pharmaceuticals, Inc. Npp1 fusion proteins
US9309318B2 (en) * 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
EP4162036A1 (en) 2020-06-09 2023-04-12 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083249A2 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素-21受体活性

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
UA84387C2 (ru) 1999-03-09 2008-10-27 Займодженетикс, Инк. Человеческий цитокин как лиганд зальфа рецептора и его применение
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
ES2279809T3 (es) * 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
ATE346864T1 (de) 2000-05-11 2006-12-15 Genetics Inst Llc Mu-1, ein mitglied der cytokine rezeptor familie
EP2130919A1 (en) * 2001-11-05 2009-12-09 ZymoGenetics, Inc. IL-21 antagonists
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
RU2005132458A (ru) * 2003-03-21 2006-03-20 Уайт (Us) Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
EP1753458A4 (en) * 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
MX2007001509A (es) 2004-08-05 2007-03-27 Wyeth Corp Antagonismo de la actividad del receptor de interleuquina 21.
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083249A2 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
US20040265960A1 (en) * 2003-03-14 2004-12-30 Wyeth Antibodies against human IL-21 receptor and uses therefor
CN1777621A (zh) * 2003-03-14 2006-05-24 Wyeth公司 抗人il-21受体的抗体及其应用
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素-21受体活性

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
孙稳平: "白细胞介素21及其研究进展", 《动物医学进展》 *

Also Published As

Publication number Publication date
AR071885A1 (es) 2010-07-21
IL209328A0 (en) 2011-01-31
AU2009248809A1 (en) 2009-11-26
CL2009001284A1 (es) 2009-11-27
WO2009143523A1 (en) 2009-11-26
US20120264919A1 (en) 2012-10-18
JP2011523849A (ja) 2011-08-25
EP2297199A1 (en) 2011-03-23
MY149448A (en) 2013-08-30
SA109300315B1 (ar) 2012-08-28
ZA201008335B (en) 2014-04-30
PE20100141A1 (es) 2010-02-22
RU2010152690A (ru) 2012-06-27
MX2010012811A (es) 2011-05-19
KR20110040773A (ko) 2011-04-20
TW201000129A (en) 2010-01-01
NZ589330A (en) 2012-12-21
US20090298167A1 (en) 2009-12-03
CO6382184A2 (es) 2012-02-15
CA2724915A1 (en) 2009-11-26
US8163884B2 (en) 2012-04-24

Similar Documents

Publication Publication Date Title
AU2016239858B2 (en) Antibodies to canine interleukin-4 receptor alpha
CN113248618B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
CA2780692C (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
US9340618B2 (en) IL-11R binding proteins
KR20210087094A (ko) 항-4-1bb 항체 및 이의 용도
US8163884B2 (en) Interleukin-21 receptor binding proteins
US8178097B2 (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
US20160194402A1 (en) Cd70-binding peptides and method, process and use relating thereto
KR20140019344A (ko) 스타필로코커스 아우레우스 알파 독소에 특이적으로 결합하는 항체 및 이의 사용 방법
US20250340654A1 (en) Caninized antibodies to canine interleukin-31 receptor alpha ii
KR20240026496A (ko) 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
JP2012528812A (ja) ヒトccn1に対する抗体とその用途
CN106062193A (zh) 新型与人tlr2及人tlr4结合的双特异性抗体
KR20240021959A (ko) 항개 cd20 항체
KR20220048028A (ko) 항-cd19 항체 및 그의 용도
HK1157358A (en) Interleukin-21 receptor binding proteins
US20250163186A1 (en) IgE BINDING PROTEINS AND USES THEREOF
HK1157220A (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
WO2024094159A1 (zh) 靶向人源ror1的单域抗体
WO2024230179A1 (zh) 抗人il-15的抗体及其用途
HK40110110A (en) Canine antibodies having modified ch2-ch3 sequences
CN118891282A (zh) 犬白介素-31受体αII的犬源化抗体
HK40057471A (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
HK40057471B (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157358

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110622

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1157358

Country of ref document: HK